Success Metrics

Clinical Success Rate

100.0%

Based on 1 completed trials

Completion Rate

100%(1/1)

Active Trials

1(33%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_1

33%

Ph phase_4

33%

Ph early_phase_1

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Early Phase 1First-in-human

1(33.3%)

Phase 1Safety & dosage

1(33.3%)

Phase 4Post-market surveillance

1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(1)

Detailed Status

Recruiting1

Completed1

Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Early Phase 11 (33.3%)

Phase 11 (33.3%)

Phase 41 (33.3%)

Trials by Status

recruiting133%

completed133%

enrolling_by_invitation133%

Recent Activity

1 active trials

Showing 3 of 3

recruitingphase_1

A Phase Ib Study to Evaluate the Efficacy and Safety of HRS-2129 in Patients With Knee Osteoarthritis

NCT07351968

completedphase_4

Efficacy and Safety of Ningmitai Capsule Alone or Combined With Celecoxib in the Treatment of CP/CPPS

NCT06159114

enrolling_by_invitationearly_phase_1

Shengyu Decoction and Lijin Manipulation for Knee OA: 3D Gait Analysis

NCT06451783

Clinical Trials (3)

Showing 3 of 3 trials

NCT07351968Phase 1

A Phase Ib Study to Evaluate the Efficacy and Safety of HRS-2129 in Patients With Knee Osteoarthritis

Recruiting

NCT06159114Phase 4

Efficacy and Safety of Ningmitai Capsule Alone or Combined With Celecoxib in the Treatment of CP/CPPS

Completed

NCT06451783Early Phase 1

Shengyu Decoction and Lijin Manipulation for Knee OA: 3D Gait Analysis

Enrolling By Invitation

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3